Free Trial

Wills Financial Group LLC Makes New Investment in Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo with Medical background

Key Points

  • Wills Financial Group LLC acquired 4,548 shares of Johnson & Johnson valued at approximately $754,000 during the first quarter.
  • Johnson & Johnson's latest quarterly earnings report revealed $2.77 earnings per share, exceeding estimates and marking a 5.8% increase in revenue year-over-year.
  • The company recently announced a quarterly dividend of $1.30 per share, representing an annual yield of 3.1%.
  • Five stocks we like better than Johnson & Johnson.

Wills Financial Group LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,548 shares of the company's stock, valued at approximately $754,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. JGP Global Gestao de Recursos Ltda. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $384,000. Accent Capital Management LLC grew its holdings in shares of Johnson & Johnson by 16.6% during the 1st quarter. Accent Capital Management LLC now owns 934 shares of the company's stock worth $155,000 after acquiring an additional 133 shares during the period. Strategic Investment Solutions Inc. IL grew its holdings in shares of Johnson & Johnson by 19.8% during the 1st quarter. Strategic Investment Solutions Inc. IL now owns 1,545 shares of the company's stock worth $256,000 after acquiring an additional 255 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Johnson & Johnson by 4.3% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 98,986 shares of the company's stock worth $16,416,000 after buying an additional 4,055 shares during the last quarter. Finally, Gill Capital Partners LLC grew its stake in shares of Johnson & Johnson by 4.3% in the 1st quarter. Gill Capital Partners LLC now owns 2,262 shares of the company's stock worth $375,000 after buying an additional 94 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on JNJ. Bank of America upped their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Check Out Our Latest Research Report on JNJ

Johnson & Johnson Price Performance

NYSE JNJ opened at $167.33 on Monday. The business's fifty day moving average price is $157.46 and its 200-day moving average price is $156.74. The stock has a market capitalization of $402.99 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 2.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.82 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines